Anti CD20 chimeric antigen receptor T cell therapy - Hebei Senlang Biotechnology
Latest Information Update: 25 Nov 2022
At a glance
- Originator Hebei Senlang Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Haematological malignancies
Most Recent Events
- 07 Sep 2022 Clinical trials in Haematological malignancies (Recurrent, Metastatic disease, Late-stage disease) in China (Parenteral) (NCT05618041)